LEXX on Nasdaq

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

$705.9KRevenue, fiscal 20252
-$11.9MNet income, fiscal 20252

Compare with Summit Therapeutics, Unicycive Therapeutics, Inc. or Karuna Therapeutics, or pick any stock.

  • TickerLEXX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersKelowna, Canada1
  • Incorporated inNV3
  • Business address100 - 740 Mccurdy Road, Kelowna, A1 V1X 2P73
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECH TM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

99.6%Gross margin2
-1683.0%Operating margin2
-1686.0%Net margin2
52.0%Revenue growth, 20252
-398.1%Return on equity2
-$10.5MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

IP Licensing brought in 99% of the revenue Lexaria Bioscience Corp. broke down this way in fiscal 2025.

  1. IP Licensing$696.0K299%up 52% from 2024
  2. B2B$9.9K21%up 58% from 2024
Products and services by year
Products and services20242025
IP Licensing$458.0K$696.0K
B2B$6.3K$9.9K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue0¢$2.7K
  • Research and development100¢$8.2M

Out of $705.9K in revenue.2 The company lost money this year.

Financial statements

Revenue567892$705.9K in 2025+63% since 2018
0$200.0K$400.0K$600.0K$800.0K2018: $433.3K$433.3K20182019: $222.6K$222.6K2019−49%2020: $384.5K$384.5K2020+73%2021: $722.7K$722.7K2021+88%2022: $255.4K$255.4K2022−65%2023: $226.2K$226.2K2023−11%2024: $464.3K$464.3K2024+105%2025: $705.9K$705.9K2025+52%
Gross profit56107892$703.2K in 2025+72% since 2018
0$200.0K$400.0K$600.0K$800.0K2018: $408.1K$408.1K20182019: $199.7K$199.7K2019−51%2020: $215.4K$215.4K2020+8%2021: $547.4K$547.4K2021+154%2022: $183.6K$183.6K2022−66%2023: $194.7K$194.7K2023+6%2024: $459.5K$459.5K2024+136%2025: $703.2K$703.2K2025+53%
Operating income7892-$11.9M in 2025+109% since 2021
-$15.0M-$10.0M-$5.0M02021: -$5.7M-$5.7M20212022: -$6.6M-$6.6M2022+16%2023: -$6.5M-$6.5M2023−1%2024: -$5.8M-$5.8M2024−12%2025: -$11.9M-$11.9M2025+107%
Net income11107892-$11.9M in 2025
-$15.0M-$10.0M-$5.0M0$5.0M$10.0M2018: $6.6M$6.6M20182019: $4.1M$4.1M2019−38%2020: -$4.1M-$4.1M20202021: -$4.0M-$4.0M2021−1%2022: -$7.3M-$7.3M2022+81%2023: -$6.7M-$6.7M2023−8%2024: -$5.8M-$5.8M2024−13%2025: -$11.9M-$11.9M2025+105%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-08-312024-08-31
Revenue$705.9K$464.3K
Cost of goods sold$2.7K$4.8K
Gross profit$703.2K$459.5K
Research and development$8.2M$2.4M
General and administrative$4.3M$3.9M
Total operating expenses$12.6M$6.2M
Loss from operations-$11.9M-$5.8M
Interest income$3.0K$14.3K
Unrealized loss on marketable securities-$33.7K-$69.8K
Total other income (loss)-$30.7K-$55.5K
Net loss-$11.9M-$5.8M
Less: Net loss attributable to non-controlling interest-$9.6K-$13.3K
Net loss attributable to Lexaria shareholders-$11.9M-$5.8M
Foreign currency translation adjustment-$50.5K-$19.8K
Total comprehensive loss-$12.0M-$5.8M
Basic and diluted loss per share-$0.66-$0.47
- Basic and diluted18.0M shares12.4M shares

Compare Lexaria Bioscience Corp. with another company

Leadership

Who has led Lexaria Bioscience Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard Christopher2024–now

President

  1. Leonard Macmillan2006
  2. John Martin Docherty2015–now

Chief financial officer

  1. Diane Rees2006
  2. Baljinder Bhullar2009–2015
  3. Allan Horst Spissinger2017–2020
  4. Gregory Downey2021–2022
  5. Nelson Cabatuan2024
  6. Michael Elliot Shankman2024–now
2010201520202025
Board members and other officers (15)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorChristopher Bunka named Dec 20, 2021 to Sep 21, 202635
  • DirectorTED MCKECHNIE named Dec 20, 2021 to Oct 16, 202436

Former names

  • Lexaria Corp.Mar 3, 2008 to May 11, 20163

Timeline

  1. Sep 5, 2024New chief executive Richard Christopher becomes CEO14

Filings

257 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 64 major events, 63 insider forms, 10 large holders, 8 private raises, 90 other. The latest 20:

  1. Oct 13, 2026EFFECT EDGAR
  2. Oct 13, 2026424B3 424 B3 EDGAR
  3. Oct 2, 2026S-3 EDGAR
  4. Sep 21, 2026D EDGAR
  5. Sep 9, 20268-K EDGAR
  6. Sep 1, 20268-K EDGAR
  7. Aug 17, 20268-K EDGAR
  8. Aug 10, 20268-K EDGAR
  9. Jul 30, 20268-K EDGAR
  10. Jul 13, 202610-Q EDGAR
  11. Apr 13, 202610-Q EDGAR
  12. Mar 18, 20264 PRIMARY DOCUMENT EDGAR
  13. Feb 6, 20268-K EDGAR
  14. Jan 28, 20268-K EDGAR
  15. Jan 28, 2026S-8 EDGAR
  16. Jan 14, 2026EFFECT EDGAR
  17. Jan 14, 2026424B3 EDGAR
  18. Jan 14, 202625-NSE EDGAR
  19. Jan 13, 202610-Q EDGAR
  20. Dec 29, 2025S-3 FORM S-1 EDGAR

The 257 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

14 open-market trades by officers, directors and large owners since October 2021: 13 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 30, 2025BUNKA CHRISTOPHERDirectorBuy11,900$0.91$10.8KForm 4
Jul 29, 2025BUNKA CHRISTOPHERDirectorBuy15,600$0.92$14.4KForm 4
Jul 29, 2025McKechnie William EdwardDirectorBuy5,000$0.91$4.5KForm 4
Jul 29, 2025DOCHERTY JOHN MARTINPresident & CSOBuy5,376$0.93$5.0KForm 4
Jul 29, 2025Carle VanessaSecretaryBuy750$0.91$682Form 4
Jul 29, 2025CHRISTOPHER RICHARDChief Executive OfficerBuy15,000$0.91$13.7KForm 4
Dec 3, 2024CHRISTOPHER RICHARDChief Executive OfficerBuy27,172$2.47$67.1KForm 4
Dec 2, 2024CHRISTOPHER RICHARDChief Executive OfficerBuy22,828$2.24$51.1KForm 4
Aug 12, 2024TURKEL CATHERINE C.DirectorBuy1,600$3.13$5.0KForm 4
Jul 31, 2024Carle VanessaSecretarySale2,567$4.00$10.3KForm 4
Feb 9, 2023TURKEL CATHERINE C.DirectorBuy1,500$2.84$4.3KForm 4
Oct 14, 2022Downey GregoryChief Financial OfficerBuy121$2.09$253Form 4
Oct 13, 2022BUNKA CHRISTOPHERDirectorBuy16,600$2.10$34.9KForm 4
Oct 12, 2022BUNKA CHRISTOPHERDirectorBuy21,900$1.99$43.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 9, 2026Raised $113,492 in a private offering of securities Form D: 3 investors so far Form D
  2. Dec 16, 2025Raised $3.5 million in a private offering of securities Form D: 5 investors so far Form D
  3. Sep 29, 2025Raised $4 million in a private offering of securities Form D: 5 investors so far Form D
  4. Oct 16, 2024Raised $5 million in a private offering of securities Form D: 1 investor so far Form D
  5. Apr 30, 2024Raised $364,629 in a private offering of securities Form D: 1 investor so far Form D
  6. Feb 16, 2024Raised $3.6 million in a private offering of securities Form D: 2 investors so far Form D
  7. Oct 3, 2023Raised $1.6 million in a private offering of securities Form D: 1 investor so far Form D
  8. Dec 16, 2021Raised $1.2 million in a private offering of equity Form D: 1 investor so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39